INMD
InMode Ltd. (NASDAQ)
Healthcare — Medical Devices
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Price History
Fundamentals
| Market Cap | $843.82M |
| P/E Ratio (TTM) | 10.87 |
| Forward P/E | 10.10 |
| EPS (TTM) | $1.35 |
| Dividend Yield | - |
| Profit Margin | 23.27% |
| Revenue Growth | 5.30% |
| ROE | 13.62% |
| Debt/Equity | 0.73 |
| Recommendation | Hold 3.0 |
| Analyst Target | $14.33 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 72.5 |
| Beta | 1.93 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.74 |
| 52-Week Low | $12.72 |
| 50-Day Avg | $13.96 |
| 200-Day Avg | $14.35 |
| Avg Volume | 835.6K |
| Volume | 511.2K |
Performance Analysis
NEUTRALINMD presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:15 UTC
Back to Screener Export Report